BridgeBio Pharma, Inc.
BBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $120,700 | $110,565 | $116,633 | $5,882 |
| % Growth | 9.2% | -5.2% | 1,882.9% | – |
| Cost of Goods Sold | $6,563 | $3,653 | $2,639 | $2,084 |
| Gross Profit | $114,137 | $106,912 | $113,994 | $3,798 |
| % Margin | 94.6% | 96.7% | 97.7% | 64.6% |
| R&D Expenses | $112,874 | $111,231 | $111,431 | $130,350 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $137,621 | $129,154 | $106,365 | $94,782 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $8,841 | $805 | $570 | $4,693 |
| Operating Expenses | $259,336 | $241,190 | $218,366 | $229,825 |
| Operating Income | -$145,199 | -$134,278 | -$104,372 | -$226,027 |
| % Margin | -120.3% | -121.4% | -89.5% | -3,842.7% |
| Other Income/Exp. Net | -$41,283 | -$47,380 | -$65,236 | -$40,209 |
| Pre-Tax Income | -$186,482 | -$181,658 | -$169,608 | -$266,236 |
| Tax Expense | -$1,545 | $2,100 | $0 | $1,153 |
| Net Income | -$182,743 | -$181,903 | -$167,422 | -$265,050 |
| % Margin | -151.4% | -164.5% | -143.5% | -4,506.1% |
| EPS | -0.96 | -0.95 | -0.88 | -1.4 |
| % Growth | -1.1% | -8% | 37.1% | – |
| EPS Diluted | -0.96 | -0.95 | -0.88 | -1.4 |
| Weighted Avg Shares Out | 190,517 | 190,517 | 190,145 | 189,437 |
| Weighted Avg Shares Out Dil | 190,517 | 190,517 | 190,145 | 189,437 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,239 | $3,898 | $5,385 | $4,683 |
| Interest Expense | $11,739 | $37,637 | $42,141 | $29,821 |
| Depreciation & Amortization | $1,398 | $1,317 | $1,284 | $1,367 |
| EBITDA | -$173,345 | -$142,704 | -$126,183 | -$235,048 |
| % Margin | -143.6% | -129.1% | -108.2% | -3,996.1% |